• LIRP Enables Light-Controlled Gene Therapy

  2026-08-24

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic gene expression at the translation stage, allowing transgenes to remain suppressed in darkness and become active under blue or ambient light. In mouse models of metabolic disease and retinal neovascularization, this compact switch supported reversible, tissue-compatible control of gene therapy and offered a potential safety mechanism for interrupting treatment when needed.

• Cy5 hydrazide for Nanoparticle Carbonyl Analysis

  2026-08-24

  Cy5 hydrazide converts accessible aldehyde and ketone groups into a far-red fluorescence readout for protein carbonylation, oxidized glycoproteins, oligonucleotides, and nanoparticle-associated biomolecules. This workflow pairs covalent carbonyl detection with FAST nanoparticle characterization while addressing the dye’s low aqueous solubility through controlled DMSO handling and rigorous cleanup.

• 15-PGDH Inhibition Supports Muscle Repair During Weight Loss

  2026-08-23

  A 2026 PNAS study identifies 15-PGDH inhibition as a strategy to improve skeletal muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. The work connects prostaglandin metabolism with muscle stem cell activity and regenerated myofiber growth, while showing that combined treatment can preserve the weight-loss effect of semaglutide.

• EdU Imaging Kits (Cy3) for Osteosarcoma

  2026-08-22

  EdU Imaging Kits (Cy3) convert S-phase DNA synthesis into a bright, denaturation-free Cy3 signal for microscopy and flow cytometry. This practical workflow shows how to quantify proliferation and treatment response in cisplatin-sensitive and resistant osteosarcoma models while avoiding common fixation, background, and interpretation errors.

• FOXM1–ERα Networks in Female Lung Adenocarcinoma

  2026-08-22

  The reference study integrates public transcriptomic data with ceRNA modeling and cellular experiments to investigate FOXM1 in female lung adenocarcinoma. Its central contribution is a candidate DGCR5–hsa-miR-204-5p–FOXM1–ESR1/ERα regulatory network, alongside evidence that FOXM1 influences tumor-cell growth, apoptosis, receptor interactions, and modeled immunotherapy sensitivity.

• EdU Imaging Kits (Cy3) for S-Phase Assays

  2026-08-21

  EdU Imaging Kits (Cy3) provide antibody-free fluorescent detection of DNA synthesis during S phase. The 5-ethynyl-2'-deoxyuridine imaging kit uses CuAAC click chemistry with Cy3 azide for microscopy and flow cytometry, while avoiding DNA denaturation required by many BrdU workflows.

• miR-24-3p, Sp1/PI3K, and Doxorubicin Heart Failure

  2026-08-20

  The reference study identifies miR-24-3p as a pathogenic regulator of doxorubicin-induced heart failure, linking its direct suppression of Sp1 to reduced PI3K signaling, oxidative stress, and cardiomyocyte apoptosis. By combining rat and H9c2 models with pathway inhibitors, genetic manipulation, and dual-luciferase validation, the work provides a useful mechanistic framework for studying myocardial injury while highlighting important limits for therapeutic interpretation.

• CCT007093 Workflow for PPM1D Pathway Studies

  2026-08-20

  CCT007093 is a DMSO-soluble PPM1D inhibitor for connecting phosphatase activity with P38 kinase activation, pyroptosis, and cancer-cell responses. This guide translates its biochemical and cellular profile into practical workflows for breast cancer and kidney-injury models, with controls and troubleshooting steps that help distinguish pathway engagement from nonspecific toxicity.

• EdU Imaging Kits (Cy3) for HNSCC S-Phase

  2026-08-19

  EdU Imaging Kits (Cy3) translate DNA replication into a bright Cy3 signal for microscopy, flow cytometry, and quantitative tumor-microenvironment studies. This practical guide adapts the assay to CCR7/DUSP1 iCAF experiments, co-culture models, drug-response screens, and genotoxicity testing while preserving morphology and antigen accessibility.

• (-)-JQ1 Controls for BRD4 Assays

  2026-08-19

  (-)-JQ1 is a cell-permeable JQ1 stereoisomer used to separate BET bromodomain engagement from vehicle, handling, and nonspecific treatment effects. This guide shows how to deploy it in BRD4-dependent cell line studies, epigenetics research, and inv(16) AML workflows inspired by a recent N-MYC/eIF4G1 study.

• SMPD4, Ceramide, and Primary Cilia in Brain Development

  2026-08-18

  The 2024 Development study identifies SMPD4-dependent ceramide production as a key requirement for primary-cilium formation, neural progenitor survival, and brain development. By combining a mouse model with human SMPD4-deficient induced pluripotent stem cells and a ceramide-rescue experiment, the authors connect sphingolipid metabolism to microcephaly and cerebellar hypoplasia.

• Ozone, Efferocytosis, and Neuropathic Pain

  2026-08-18

  Ruan et al. identify macrophage efferocytosis as a mechanistically important component of ozone-mediated relief of neuropathic pain. In a chronic constriction injury model and complementary macrophage experiments, ozone activated an AMPK/Gas6-MerTK/SOCS3 axis, increased apoptotic-cell clearance, and reduced inflammatory signaling, although translational validation remains necessary.

• G-15: GPR30 Antagonist Research Workflow

  2026-08-17

  G-15 is a selective G protein-coupled estrogen receptor antagonist for separating GPR30 signaling from ERα and ERβ activity. This workflow connects receptor pharmacology with calcium, PI3K/Akt, proliferation, endoplasmic-reticulum-stress, and immune-function readouts.

• PDE-5-Silenced BMSCs in Diabetic Cardiac Fibrosis

  2026-08-17

  The reference study shows that bone marrow mesenchymal stem cells with suppressed PDE-5 expression reduce high-glucose-associated fibrotic signaling and cardiomyocyte injury phenotypes in a co-culture model. Its central contribution is to connect BMSC-mediated cardiac protection with restoration of the cGMP/PKG pathway, while also highlighting the need for in vivo and pathway-blockade validation.

• Streptozotocin Workflows for Diabetes Research

  2026-08-16

  Streptozotocin enables controlled β-cell injury, hyperglycemia, and downstream diabetes-complication studies when formulation, dosing, and validation are tightly standardized. This workflow connects STZ-based metabolic models with modern pain, microglia, and pyroptosis assays while emphasizing practical troubleshooting and model limitations.

8565 records 4/571 page Previous Next 12345 下5页 Last page